Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed "This post ...
Recent U.S. Food and Drug Administration interactions have provided the opportunity to initiate a pivotal expansion of the ...
"The standard treatment for DVT has been anticoagulation and there has not been a meaningful change in standard of care for ...
New proprietary Thykamine ™ 0.1% formulation expands Devonian's clinical development program into supportive oncology, with a ...
(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the ...
According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual ...
Since the interim data cut reported in the accepted manuscript, CAMPX has completed patient enrollment and Last Patient, Last ...
New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive ...
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for ...
MORRISVILLE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Syneos Health® today announced a partnership with Optum to build a more ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results